Vraylar (Cariprazine HCl) Patent Expiration, LOE Window & CMS Spending

Vraylar (Cariprazine HCl) by AbbVie: FDA Orange Book core substance LOE 2030-03-17, 0 AB generics, $2.61B 2024 CMS Part D & Medicaid spend, and $1,519 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN204370 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-03-17
Last Listed Patent or Exclusivity Date2030-03-17
Orange Book Patents (*PED Extensions)12 patents (6 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.61B
2024 Medicare Part D Spend$1.14B
2024 Medicaid Spend$1.47B
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,519 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.